A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
Sponsor: AbbVie
This PHASE3 trial investigates Psoriatic Arthritis and is currently completed. AbbVie leads this study, which shows 38 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
38 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 33 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
Status: Enrolling By Invitation → Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Enrolling By Invitation PHASE3
-
May 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .